Clinical Trials e-Newsletter: Patients Should Ask-in On Clinical Trials Participation

Clinical Trials e-Newsletter | May 2019

Ask-in On Clinical Trials

Ask-in: Talk to Your Doctor about Clinical Trials

You may be eligible to receive treatment with a cutting-edge therapy with great healthcare at no cost through a clinical trial. Early access to these treatments via clinical trials have been life-saving for many. PHEN’s surveys from its educational events indicate that approximately 60% of patients would consider participating in a clinical trial if it could benefit them. Ask your doctor about enrolling in a clinical trials and the potential benefits they you may receive. It may be good to get second opinions.

* Clinical Trials Focus: Galahad Clinical Trial *

Patients with metastatic (spreading) prostate cancer who have progressed on prior chemotherapy and hormone therapy treatment should consider the Galahad clinical trial. This phase 2 trial is studying the safety and effectiveness of the drug niraparib in patients with certain genetic alterations within their tumors. Click here to learn more about this clinical trial.

African American Prostate Cancer Patients should Consider Biomarker Testing

Biomarker testing is available for prostate cancer to help determine whether to treat our select active surveillance, and to assist in other diagnosis to help doctors make more accurate clinical decisions. Dr. Todd Cohen, VP Medical Affairs, Myriad Genetics presented on this topic at PHEN’s May 8th webcast. Click here to view his presentation . PHEN president Thomas Farrington posted this blog: Biomarker Testing Needed Before African American Patients Choose Active Surveillance.

What to Expect During Androgen Deprivation Therapy (ADT)?

Patients diagnosed with Prostate Cancer are commonly treated with Androgen Deprivation Therapy, such as Lupron, in order to keep their testosterone levels low to help fight the cancer and delay progression. Click here to learn more about what to expect from ADT.

PHEN’s Clinical trials "FYT" Tool Update

The Find Your Trial (FYT) Tool allows you to easily search for phase 2-4 actively-recruiting prostate cancer clinical trials to help you identify which trials may be right for you. Take a look at these FYT tool searches:

P atients with Low and Intermediate Risk Prostate Cancer

High Risk Prostate Cancer Patients

Patients Treated with Prostatectomy or Radiation

Patients with Recurrent Prostate Cancer

Patients with Castration Resistant Prostate Cancer (CRPC)

Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients

Understanding Castration Resistant Prostate Cancer

Androgen deprivation (hormone) therapy, such as Lupron, works to reduce testosterone in the body to castration levels to prevent or slow the progression of prostate cancer.

What is Castration resistant Prostate Cancer?

Prostate cancer becomes Castration Resistant when the cancer progresses despite treatment with anti-androgen therapy.

What is non-Metastatic Castration Resistant Prostate Cancer?

Castration Resistant Prostate Cancer where no metastases have been detected.

What is Metastatic Castration Resistant Prostate Cancer?

Castration Resistant Prostate Cancer that has spread and metastasized to other parts of the body such as bones and other organs.

* Clinical Trial Focus: IPATential150 *

For patients with metastatic (spreading) castration-resistant prostate cancer who are eligible for abiraterone (Zytiga) but have not yet begun this treatment, consider the IPATential150 clinical trial. This phase 3 trial is studying the safety and effectiveness of adding the drug ipatasertib to the current standard of care for patients. Click here to learn more about this clinical trial.